ConductScience.org, home

Paper37623652

Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers.

Anisuzzman M and 3 others. J Funct Biomater, 2023. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers. Papers, record 37623652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37623652

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers.
PubMed
Journal
J Funct Biomater
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
1.19
iCite
Revised in PubMed
2023-08-29
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Anisuzzman MMohammad
2Komalla VVarsha
3Tarkistani MAMMariam Abdulaziz Mhttps://orcid.org/0000-0002-6829-1508
4Kayser VVeyselhttps://orcid.org/0000-0003-1310-9534

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130318080Nimotuzumab: beyond the EGFR signaling cascade inhibition.Semin Oncol2018https://conductscience.org/library/papers/30318080PubMed
228741619Pancreatic Cancer: EGFR inhibition is effective against KRAS-wild-type disease.Nat Rev Clin Oncol2017https://conductscience.org/library/papers/28741619PubMed
320410458Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20410458PubMed
428674498Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.Front Pharmacol2017https://conductscience.org/library/papers/28674498PubMed
534294133Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.J Exp Clin Cancer Res2021https://conductscience.org/library/papers/34294133PubMed
623631767Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo.ACS Nano2013https://conductscience.org/library/papers/23631767PubMed
728347065Conjugation of Polymer-Coated Gold Nanoparticles with Antibodies-Synthesis and Characterization.Nanomaterials (Basel)2015https://conductscience.org/library/papers/28347065PubMed
830004227Characterizing the Surface Coverage of Protein-Gold Nanoparticle Bioconjugates.Bioconjug Chem2018https://conductscience.org/library/papers/30004227PubMed
929504398Biomimetic Viruslike and Charge Reversible Nanoparticles to Sequentially Overcome Mucus and Epithelial Barriers for Oral Insulin Delivery.ACS Appl Mater Interfaces2018https://conductscience.org/library/papers/29504398PubMed
1033257670Enhanced dispersion stability of gold nanoparticles by the physisorption of cyclic poly(ethylene glycol).Nat Commun2020https://conductscience.org/library/papers/33257670PubMed
1131554850Cisplatin bioconjugated enzymatic GNPs amplify the effect of cisplatin with acquiescence.Sci Rep2019https://conductscience.org/library/papers/31554850PubMed
1231921818Cytotoxicity-Related Bioeffects Induced by Nanoparticles: The Role of Surface Chemistry.Front Bioeng Biotechnol2019https://conductscience.org/library/papers/31921818PubMed
1332945225Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy.Nanomedicine (Lond)2020https://conductscience.org/library/papers/32945225PubMed
1419803497Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation and biomolecular binding studies.Anal Chem2009https://conductscience.org/library/papers/19803497PubMed
1532657634Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of 177Lu-Nimotuzumab.Int J Radiat Biol2020https://conductscience.org/library/papers/32657634PubMed
169449346Correlation between surface morphology and surface forces of protein A adsorbed on mica.Biophys J1998https://conductscience.org/library/papers/9449346PubMed
1721150278Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.Cancer Biol Ther2011https://conductscience.org/library/papers/21150278PubMed
1820121172One-phase synthesis of water-soluble gold nanoparticles with control over size and surface functionalities.Langmuir2010https://conductscience.org/library/papers/20121172PubMed
1924990295Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model.Nanotechnology2014https://conductscience.org/library/papers/24990295PubMed
2031698869Tumor Targeting by Monoclonal Antibody Functionalized Magnetic Nanoparticles.Nanomaterials (Basel)2019https://conductscience.org/library/papers/31698869PubMed

See all 47 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
40124344Treatment of lung diseases via nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments?Mater Today Bio2025https://conductscience.org/library/papers/40124344PubMed
39940134Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting.Nanomaterials (Basel)2025https://conductscience.org/library/papers/39940134PubMed
37803407Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches.Mol Cancer2023https://conductscience.org/library/papers/37803407PubMed
37762316An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC.Int J Mol Sci2023https://conductscience.org/library/papers/37762316PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37623652

GET https://conductscience.org/api/papers/v1/37623652/references?page=2